Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate)GlobeNewsWire • 11/22/19
Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal DisorderGlobeNewsWire • 11/21/19
Biogen's Alzheimer's Drug Goes From Bust to Boon, Plus Why Walgreens Is Shuttering 200 Healthcare ClinicsThe Motley Fool • 11/08/19
Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung BioepisGlobeNewsWire • 11/06/19
FDA verdict on Biogen's Alzheimer's drug likely to be a 'political decision,' analyst saysCNBC • 11/04/19